Charles Schwab Investment Management Inc. Has $357,000 Holdings in Contineum Therapeutics, Inc. $CTNM

Charles Schwab Investment Management Inc. cut its position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 7.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,202 shares of the company’s stock after selling 4,128 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.20% of Contineum Therapeutics worth $357,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Red Tree Management LLC acquired a new position in Contineum Therapeutics in the 4th quarter valued at $9,349,000. Stempoint Capital LP acquired a new position in Contineum Therapeutics in the 4th quarter valued at $3,894,000. Northern Trust Corp grew its stake in Contineum Therapeutics by 42.3% in the 4th quarter. Northern Trust Corp now owns 89,262 shares of the company’s stock valued at $1,308,000 after buying an additional 26,545 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Contineum Therapeutics in the 4th quarter valued at $1,001,000. Finally, Barclays PLC grew its stake in Contineum Therapeutics by 96.0% in the 4th quarter. Barclays PLC now owns 16,286 shares of the company’s stock valued at $239,000 after buying an additional 7,978 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. William Blair assumed coverage on shares of Contineum Therapeutics in a research note on Friday, June 20th. They issued an “outperform” rating on the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $31.00 target price on shares of Contineum Therapeutics in a research note on Thursday, May 15th. Finally, Morgan Stanley increased their price target on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Monday, August 18th. One research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $22.75.

Contineum Therapeutics Stock Performance

NASDAQ:CTNM opened at $10.58 on Thursday. The company has a 50-day moving average of $6.37 and a 200-day moving average of $5.67. The company has a market capitalization of $296.66 million, a price-to-earnings ratio of -4.81 and a beta of 1.19. Contineum Therapeutics, Inc. has a 52 week low of $3.35 and a 52 week high of $20.30.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Sell-side analysts forecast that Contineum Therapeutics, Inc. will post -2.01 EPS for the current year.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).